Malassezia Sympodialis (Mala s 6) IgE Test · Blood

If you have stubborn eczema on your face, scalp, or neck that flares despite the usual creams, a skin yeast called Malassezia may be quietly driving the inflammation. This test looks for IgE antibodies (allergy antibodies) your immune system has built against one specific protein from that yeast, called Mala s 6.

A positive result points to an allergic reaction to a microbe that lives on nearly everyone's skin, but only triggers immune trouble in some. It can reframe a frustrating skin condition as something more targeted, with specific treatment options worth discussing with your dermatologist.

What This Test Actually Measures

Mala s 6 (full name: Malassezia sympodialis allergen 6) is a protein made by the skin yeast Malassezia sympodialis. Scientifically, it belongs to a family of helper proteins called cyclophilins. What matters for you is that some people's immune systems mistake this yeast protein for a threat and produce IgE antibodies against it. This test, run on a blood sample, looks specifically for those antibodies.

Detecting Mala s 6 antibodies tells you whether you are sensitized to this specific component. It is one of several Malassezia proteins (others include Mala s 1, 5, 9, and 11) that can drive an allergic-type response in skin. Testing a single component rather than a whole yeast extract lets you pinpoint exactly which molecule your immune system is reacting to.

Atopic Dermatitis, Especially Head and Neck

Mala s 6 IgE matters most in the context of atopic dermatitis (eczema). Across studies, somewhere between 35% and 50% of adults with atopic dermatitis show IgE antibodies to Malassezia. In the subgroup with eczema concentrated on the head and neck, a pooled meta-analysis found that roughly 79% are sensitized to Malassezia. By contrast, this kind of sensitization is rare in people without atopic dermatitis and in those with other skin conditions like seborrheic dermatitis.

In a component-level study using the ALEX2 panel, about 14% of adults with atopic dermatitis were specifically positive for Mala s 6. Within that group, having antibodies to Mala s 6 and a related component called Mala s 11 was linked to more severe disease. Mala s 6 positivity has also been associated with allergic rhinitis (hay fever) in people with eczema.

Severity and Phenotype Signal

Beyond simply confirming sensitization, Malassezia-related IgE behaves as a phenotype marker. People with higher severity scores tend to have higher levels and broader patterns of reactivity. Two patterns repeat across studies: head-and-neck distribution and male sex are both associated with a higher chance of being sensitized to Malassezia.

Source: Brodská et al. (Dermatitis, 2014); See Tow & Yew (Experimental Dermatology, 2024); Čelakovská et al. (Journal of Fungi, 2021).

What this means for you: if you have moderate-to-severe eczema, particularly on the face, scalp, or neck, a positive Mala s 6 result helps explain why the inflammation is so persistent and points toward a specific biological driver rather than a vague trigger.

Children, Food Allergy, and Other Atopic Disease

Sensitization is not just an adult phenomenon. In pediatric cohorts, 17% to 27% of children with atopic dermatitis carry Malassezia-specific IgE, and it has been detected in infants as young as four months. One ten-year follow-up of 187 children showed that infants with severe atopic dermatitis combined with food allergy were at greater risk of developing Malassezia sensitization over time.

In adults, sensitization to Mala s 6 and related fungal components also clusters with allergic rhinitis and, in some patterns, asthma. The biomarker therefore sits inside a broader allergic profile rather than standing on its own.

Why One Reading Is Not Enough

A single Mala s 6 result is a snapshot of your current sensitization. IgE levels for any given allergen can shift over months and years as exposure, treatment, and overall skin inflammation change. Tracking the trend tells you more than any one number, especially if you are starting a new therapy or trying to identify drivers of a persistent flare.

A practical cadence: get a baseline now, retest in three to six months if you are starting targeted treatment or changing your skin care routine substantially, then check at least annually if you have a Malassezia-driven phenotype. Comparing your own trajectory over time is more useful than comparing your number to a population reference.

What to Do With an Unexpected Result

A positive Mala s 6 result, especially with head and neck eczema, is a reason to take it to a dermatologist or allergist who works with component-resolved allergy testing. Pair this result with a total IgE level, environmental allergen IgE (dust mite, pollens, animal dander), and an assessment of severity (such as a SCORAD or EASI score) to build a fuller picture.

If your test is negative but you still suspect a yeast-driven phenotype, remember that single-species testing can miss roughly 20% of patients sensitized to other Malassezia species. Asking about a broader Malassezia mix or wider component panel can clarify the picture. In small clinical series, people with Malassezia-sensitized head and neck eczema have responded well to targeted antifungal therapy (oral itraconazole or topical ketoconazole), so a positive result can open a specific treatment conversation that standard eczema care misses.

When Results Can Be Misleading

Two limitations matter most. First, a negative result on a single-species or single-component assay does not rule out Malassezia involvement, because allergens differ between Malassezia species and not all panels include Mala s 6. Second, sensitization is not the same as clinical disease: a positive IgE means your immune system recognizes the yeast, but the result must be interpreted alongside your symptoms, skin distribution, and severity.

Standardized clinical cutpoints for Mala s 6 do not yet exist. This is a research-grade component test, useful for phenotyping in the right context but not for diagnosing eczema on its own. The diagnosis comes from a clinician's exam; the IgE result helps explain a piece of the biology.